Programs

ONE MIND has numerous projects at various stages of development. The following are our flagship initiatives, which have been in development for over a year and are positioned for full operational launch in 2013.

1 in 3 people will suffer brain illness or injury in their lifetime.
Brain diseases and injuries cost society as much as $2 TRILLION per year in the US and EU.
Brain disorders and injuries cost society more than cancer and cardiovascular disease COMBINED.
1.7 MILLION Americans have Autism.
1.7 MILLION Americans suffer a Traumatic Brain Injury every year.
Approximately 1 million Americans suffer from Parkinson’s disease.
Over 5 million Americans have Alzheimer’s Disease.
For every soldier killed in war in 2012, about 25 veterans took their own lives.
Traumatic Brain Injury (TBI) is one of the LEADING CAUSES OF DEATH AND DISABILITY in America.
By 2023, over 46 million American adults will suffer from a mental disorder.
53,000 Americans die every year due to Traumatic Brain Injury.
8 teenagers die EVERY DAY in the US from TBI.
Neurological disorders constitute 12% of total deaths globally each year.
There are 5 MILLION Americans living with TBI-related disabilities.
Mental disorders make up 35% of the cost of all non-communicable diseases worldwide.
5.3 MILLION Americans have lifelong disabilities due to Traumatic Brain Injury (TBI).
Direct and indirect cost of TBI is $76 BILLION per year in the US.
Nearly 8% of the US population suffers from POST-TRAUMATIC STRESS in their lifetime.
300,000 soldiers suffer TBI and/or PTS.
Women are about twice as likely as men to develop PTSD.
There is 1 military suicide per day in the US.
FOUR people commit suicide EVERY HOUR in the United States.
In the U.S., serious mental illness causes earnings loss of $193.2 billion annually.
90% of suicide victims have a TREATABLE MENTAL DISORDER.
Nearly 10% of people with SCHIZOPHRENIA commit suicide.
Number one sport per capita for traumatic brain injury is GIRLS SOCCER.
HALF A MILLION children under 14 go to the emergency room every year for TBI.
Funding for brain research from government and pharmaceutical companies is DECREASING EVERY YEAR.
Someone develops Alzheimer’s Disease EVERY 68 SECONDS.
Alzheimer’s Disease is the 6th LEADING CAUSE OF DEATH in US adults.
Traumatic brain injury is the leading cause of death and disability in children and young adults.
TBI patients are up to 5 times more likely to develop Alzheimer’s disease.
Medicaid and Medicare spend $130 BILLION per year on Alzheimer’s patients.
One in 10 high school athletes involved in contact sports sustain a concussion each year.
Over 400,000 Americans have Multiple Sclerosis.
An athlete who sustains a concussion is 5 times more likely to sustain a second concussion.
People with TBI are nearly twice as likely to report binge drinking.
The lowest rates of Multiple Sclerosis are in countries nearest to the EQUATOR.
20% of U.S. troops returning from combat tours show symptoms of PTSD or major depression.
DEPRESSION is the LEADING CAUSE of disease burden in the U.S.
Nearly 7% of American adults had a MAJOR DEPRESSIVE EPISODE in the past 12 months.
81.1 million people will be affected by dementia by 2040.
Over 2 MILLION Americans over the age of 18 suffer from BIPOLAR DISORDER.
About one in 10 individuals will have at least one epileptic seizure in their lifetime.
TBI victims are 50% more likely to suffer from depression.
Over 2 MILLION Americans have SCHIZOPHRENIA.
Among people with MS, physical disability contributes to a nearly 70% unemployment rate.
The annual medical cost of Schizophrenia in the US is OVER $32B.

Programs

Programs

THE GEMINI PROGRAM

Knowledge Integration Network (KIN) for Traumatic Brain Injury (TBI) and Post- Traumatic Stress (PTS)

 

GEMINI is a Public-Private Partnership combining best-in-class science, technology, and expertise.  One Mind is catalyzing collaboration between international research centers of excellence, industry, and government to accelerate the translation of basic science into breakthrough diagnostics and improved treatments for TBI & PTS.

TBI affects an estimated 10 million people worldwide and more than 1.7 million in the U.S. every year.  TBI is a silent epidemic – its symptoms are frequently invisible, thus difficult to diagnose and treat.  TBI can lead to motor, cognitive, and social impairments that interfere with an individual’s ability to be productive. Gemini will accelerate advancements in diagnosis and treatment for veterans and civilians alike. Service members and veterans account for only 1% of TBI cases in the United States each year.

PTS is a severe anxiety disorder that follows an experience causing psychological trauma.  Early evidence suggests that as many as 20% of the approximately 1.64 million U.S. troops returning from deployments to Afghanistan and Iraq show symptoms of PTS or major depression, making PTS the most common serious injury of these wars.  It is also estimated that 8% of Americans will, in their lifetime, experience PTS from a traumatic event (e.g., sexual assault, domestic violence, crime victims, severe storms, first responders to violent crime).

In 2013, One Mind will launch this multi-country, multi-site initiative to create a large-scale database of individuals with acute head trauma and/or psychological trauma with rigorous biomarker (e.g., genetics, imaging) and clinical measures to:

  • Identify biological indicators of the causes and effects of diseases, or pathology.
  • Investigate disease progression for earlier, more accurate diagnosis and treatment.
  • Create new ways to share data between academia, industry, non-profits and government.
  • Empower patients to take a more active role in their own care, thereby contributing to the acceleration of research.

ORION BIONETWORKS: MULTIPLE SCLEROSIS

One Mind has joined the Orion Bionetworks Alliance for Multiple Sclerosis. Orion is a program of the Marin Community Fund, a non-profit 501(c)(3) corporation. Orion Bionetworks is a multidisciplinary computational modeling community that harnesses the power of data, technology, and collaboration to pave the way for Systems Medicine and transform the research and treatment of multiple sclerosis and other brain disorders.

Orion Bionetworks Mission

We are developing causal disease models with unprecedented predictive power that will drive progress towards better treatments and, ultimately, cures for multiple sclerosis and other devastating brain disorders.

To advance the understanding of brain disorders, Orion Bionetworks is building powerful, data-driven disease models.

  • To make real progress, we have to use systems biology to understand how numerous complex, nonlinear biological and patient factors interact to cause brain disorders.
  • We are creating a framework to advance causal disease models using computational tools to integrate diverse biological and clinical data from registries and repositories.
  • These disease models will be continually refined and improved through collection of new high-dimensional, quality data validated against real-world patient data.

A unique cooperative alliance model enables sustainable, multidisciplinary collaboration.

  • No one entity has the full array of resources needed to advance the research and treatment of multiple sclerosis.
  • In Orion BioNetworks, complementary stakeholders contribute patient data, expertise, computational models, IT capabilities or funds to support the coordinated development of next-generation models.
  • All Alliance partners have access to data contributed to the Data Commons through a Data Exchange Portal with Analytics Capabilities.

PHASE I: The initial program integrates clinical, biomarker and imaging data from existing databases of over 7,000 patients into a first-generation causal MS disease model. Program partners: Accellerated Cure Project for MS; Brigham Women’s Hospital, GNS Healthcare; MetaCell; PatientsLikeMe. Funding Partner: Janssen Pharmaceutical Research. This phase successfully launched in January of 2013.

PHASE II: Use combined, prospectively collected imaging, biomarker and deep phenotypic data from an additional 2000-3000 patients.

PHASE III: Model 3.0 will be focused on identifying response biomarkers to MS treatments.

www.orionbionetworks.org

Additional Programs & Partnerships

ALZHEIMER’S DISEASE & DEMENTIA. We are, in cooperation with numerous partners, developing a comprehensive strategy to advance research in Alzheimer’s and dementia, two diseases that impose a rapidly growing burden on millions.


THE ALZHEIMER’S DISEASE AND DEMENTIA LEADERSHIP COUNCIL (ADDLC). The ADDLC was launched in November 2011 in partnership with the New York Academy of Sciences (NYAS) and has formed four working groups focused on Basic Research, Early Development and Translational Research, Prevention Trials, and Policy for Public Private Partnerships. This collective effort will drive recommendations for a global strategy and Program for AD and Dementia. 

BRAIN CANADA. One Mind has also established a partnership with Brain Canada, wherein jointly prioritized programs in the Global Brain Disorders Strategic Roadmap will be funded by both organizations. Brain Canada has federal budget commitments of $100 million to match private funding for brain research.

GUARDIAN ANGELS ZERO POWER BIOSENSORS. ONE MIND and the Europe-based Guardian Angels For Smarter Life (“GA”) are allied to design research projects in North America using the revolutionary GA Zero Power Biosensors. Their potential for analysis, monitoring and treatment of major brain diseases will revolutionize brain science. An early goal of this alliance is to enable monitoring of the evolution of the Alzheimer’s. These biosensors will establish a thorough understanding of the disease’s progression on physical and bio-chemical processes in the body thereby determining how they affect the quality of life of the patient.

EDUCATION AND OUTREACH. We are drafting a strategic plan for expanding public awareness and understanding of brain disorders and injuries in order to eliminate the stigma, shame, and discrimination associated with mental illness. The campaign, which will launch in 2013, will include PSA’s, print advertising, social media, radio and television, and the internet.